GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
An oral presentation at the annual meeting of the European Congress of Rheumatology (EULAR) has detailed positive results from a Phase III study of brodalumab (KHK4827). 17 June 2019
Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo. 15 June 2019
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
Bimekizumab is a crucial pipeline drug for UCB – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker. 14 June 2019
Positive topline results from the Phase III PEMPHIX study show Rituxan (rituximab) compares favorably as a therapy for the rare, serious and potentially life-threatening condition pemphigus vulgaris (PV). 14 June 2019
Hutchison China MediTech, also known as Chi-Med, today announced that the independent Data Monitoring Committee (IDMC) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) has completed a planned interim analysis. 14 June 2019
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Convincing physicians that their drug is a better option than AbbVie’s Humira has been an aim of a lot of companies at the EULAR congress again this year – with the Chicago-based drugmaker among them. 13 June 2019
UK pharma major GlaxoSmithKline has teamed up with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in a five-year collaboration. 13 June 2019
London and New York-listed Mereo BioPharma will regain rights to etigilimab from Celgene, as the American firm elected not to exercise an option on the candidate. 13 June 2019
Privately-held Akrevia Therapeutics today announced that Joseph Farmer has been appointed as chief operating officer of the biopharma company launched by Atlas Ventures and F-Prime last September. 13 June 2019
Shares in CymaBay Therapeutics fell by about 50% on Tuesday, after 12-week top-line results showed the firm’s nonalcoholic steatohepatitis (NASH) candidate seladelpar failed to outperform placebo. 13 June 2019
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, says it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa's cell therapies for research, clinical development and commercialization in China. 13 June 2019
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Rare diseases specialist Swedish Orphan Biovitrum saw its shares gain nearly 3% to 175.50 kronor by mid-afternoon, after it revealed plans to take full control of a investigational compound that it had previously only licensed. 12 June 2019
Oncologie, a company that is using proprietary biomarkers to drive development of new drugs for cancer, has closed an $80 Series B financing. 12 June 2019
Swiss oncology-focused drug discovery firm ADC Therapeutics today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross proceeds raised in the Series E financing to $276 million. 12 June 2019
Texas-based regenerative medicine and cell therapy company InGeneron has raised a further $23 million to advance a pivotal program in rotator cuff tendinopathy, a degenerative and often chronic condition found in a person’s shoulder. 12 June 2019
Denmark’s Novo Nordisk has presented new safety data from the PIONEER 6 trial, testing its landmark oral formulation of the biologic semaglutide, compared with placebo, both in addition to standard of care. 12 June 2019